Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of ALTB-168 in Patients With Moderate to Severe Active, Anti-TNF Alpha and/or Anti-integrin Refractory Ulcerative Colitis: a 26-week, Open-label, Multi-center, Phase II Proof of Principle Trial

NCT03298022 is registered in ClinicalTrials.gov with AltruBio Inc. as lead sponsor.

NCT NCT03298022
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03298022 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of ALTB-168 in Patients With Moderate to Severe Active, Anti-TNF Alpha and/or Anti-integrin Refractory Ulcerative Colitis: a 26-week, Open-label, Multi-center, Phase II Proof of Principle Trial
Lead sponsor
AltruBio Inc.
Phase
Phase 2
Overall status
Terminated
Start date
May 4, 2018
Completion date
June 1, 2020
Enrollment
24 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis